Human Papillomavirus

FDA Approves HPV Vaccine for People Through Age 45

FDA Approves HPV Vaccine for People Through Age 45

US Food and Drug Administration approval of the Gardasil 9 HPV vaccine has been expanded to include people ages 27 through 45.

High-Risk HPV Infection Linked With Cardiovascular Disease in Women

High-Risk HPV Infection Linked With Cardiovascular Disease in Women

By

Women with high-risk human papillomavirus are at higher risk for developing cardiovascular disease than women without high-risk HPV

HPV Vaccination Decreases High-Grade Cervical Lesions in Women

HPV Vaccination Decreases High-Grade Cervical Lesions in Women

By

From 2008 to 2015, both cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ rates and cervical cancer screening declined in women age 18 to 24 years.

CDC: HPV Vaccination Rates Increasing Among Adolescents

CDC: HPV Vaccination Rates Increasing Among Adolescents

Proportion of teens up to date with HPV vaccines also increasing; reached 48.6 percent in 2017.

Oral High-Risk HPV Prevalence Appears to Be Low in England

Oral High-Risk HPV Prevalence Appears to Be Low in England

The prevalence of oral high-risk HPV infection in adult men and women is low in England.

Catch-Up HPV Vaccination Only Effective for Certain Ages

Catch-Up HPV Vaccination Only Effective for Certain Ages

By

Catch-up quadrivalent HPV vaccination with 3 doses was effective against the risk for CIN2+ and CIN3+ in girls and women age 14-20 at time of first vaccine dose but not for women age 21 and older at first dose.

Adolescent Sexual Behaviors Unaffected by HPV Legislation

Adolescent Sexual Behaviors Unaffected by HPV Legislation

Implementation of state legislation relating to HPV vaccination is not associated with changes in adolescent sexual behaviors.

Primary HPV testing may detect cervical neoplasms earlier and more accurately than cytology

In this Canadian, randomized controlled trial, the use of primary HPV testing compared with cytology resulted in a significantly lower likelihood of CIN3+ at 48 months.

No Higher Risk of Autoimmune Disorders After HPV4 Vaccination

No Higher Risk of Autoimmune Disorders After HPV4 Vaccination

Following quadrivalent human papillomavirus (HPV4) vaccination, girls age 12 to 17 years do not have increased risk of autoimmune disorders.

HPV Vaccine Eliminates Advanced Skin Cancer in 97-Year-Old

HPV Vaccine Eliminates Advanced Skin Cancer in 97-Year-Old

The 9-valent HPV vaccine could be a therapeutic option for patients with cutaneous squamous cell carcinoma when surgical management is not an option.

Primary Cervical HPV Testing Reduces High-Grade Cervical Neoplasia at 48 Months

Primary Cervical HPV Testing Reduces High-Grade Cervical Neoplasia at 48 Months

By

In women undergoing cervical cancer screening, the use of primary HPV testing compared with cytology testing results in a significantly lower likelihood of cervical intraepithelial neoplasia grade 3 or higher at 48 months.

HPV Vaccine Under Priority Review for Expanded Age Range

HPV Vaccine Under Priority Review for Expanded Age Range

By

Specifically, the types the vaccine protects against are HPV 16, 18, 31, 33, 45, 52, 58 (which cause ~90% of cervical cancer cases worldwide), and types 6 and 11 which case genital warts.

Provider Engagement With Hesitant Parents May Increase HPV Vaccination Rates

Provider Engagement With Hesitant Parents May Increase HPV Vaccination Rates

By

Investigators examined parental hesitancy when discussing human papillomavirus vaccination with providers.

Addressing Parents' HPV Vaccine Hesitancy Ups Vaccination Rates

Addressing Parents' HPV Vaccine Hesitancy Ups Vaccination Rates

Providers engaging parents hesitant about human papillomavirus vaccination and addressing their concerns can lead to same-day vaccinations.

Good Evidence That HPV Vaccines Protect Against Cervical Precancer

Good Evidence That HPV Vaccines Protect Against Cervical Precancer

High-certainty evidence that HPV vaccination may provide protection in adolescent girls and young women aged 15 to 26 years.

HPV Vaccination May Offer Protection Against Cervical Precancer

HPV Vaccination May Offer Protection Against Cervical Precancer

By

The authors concluded, "There is high-certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and young women aged 15 to 26," while also indicated that future studies should have long-term follow-up.

Risk of Developing Multiple Sclerosis After HPV Vaccination

Risk of Developing Multiple Sclerosis After HPV Vaccination

Investigators sought to determine the link between HPV vaccination and the risk of developing multiple sclerosis.

mRNA Assay Less Sensitive Than DNA Assay for Latent HPV

mRNA Assay Less Sensitive Than DNA Assay for Latent HPV

Based on these data and the potential change in follow-up care, the HPV mRNA assay should not be used for a primary screening tool for cervical cancer.

Findings Support Nonavalent HPV Vaccine Use in Women With HIV

Findings Support Nonavalent HPV Vaccine Use in Women With HIV

By

The HR-HPV types covered by the nonavalent HPV vaccine had similar clearance rates to HR-HPV types not included, and women infected with multiple anogenital HR-HPV types had lower rates of clearance than women infected with only 1 type.

HPV Vaccination: Should Adolescents Be Allowed to Give Consent?

HPV Vaccination: Should Adolescents Be Allowed to Give Consent?

By

Adolescent consent may help minimize delays in vaccination and reduce the overall incidence of cervical, oropharyngeal, and anal cancers.

Improving HPV Vaccination Rates via Bundled Intervention

Improving HPV Vaccination Rates via Bundled Intervention

A bundled intervention including communication skills training and performance feedback may improve human papillomavirus vaccination.

HPV Vaccine Completion Rates in Adolescents Improve With Physician Communication

HPV Vaccine Completion Rates in Adolescents Improve With Physician Communication

For adolescents, a health care professional HPV vaccine communication intervention is associated with improved HPV vaccine series initiation and completion.

Prevalence of HPV16 High Among HIV-Positive Men Having Sex With Men

Prevalence of HPV16 High Among HIV-Positive Men Having Sex With Men

By

Study confirms HPV16 as an important determinant of high-grade lesions and supports its place as a priority for anal cancer prevention.

Reducing Treatment of HPV+ Oropharyngeal Cancer May Compromise Safety

Reducing Treatment of HPV+ Oropharyngeal Cancer May Compromise Safety

Deintensification of treatment from chemoradiotherapy to one modality may compromise safety in patients with human papillomavirus (HPV)+ stage 1 or 2 oropharyngeal cancer.

Limitations With Herd Immunity From Vaccine-Type Human Papillomavirus

Limitations With Herd Immunity From Vaccine-Type Human Papillomavirus

By

The limitations of herd protection for vaccine-type HPV was examined in a recent study.

Seminal HPV Infection Prevalent Worldwide, May Affect Male Fertility

Seminal HPV Infection Prevalent Worldwide, May Affect Male Fertility

By

Study was the first to examine the geographical variation of seminal HPV prevalence, showing a relatively high prevalence in fertility clinic attendees when compared to the general population.

HPV-Linked Cancer Survival Rates Differ Based on Social Disparities

HPV-Linked Cancer Survival Rates Differ Based on Social Disparities

For patients with HPV-associated cancers, there are large disparities in survival based on sex, race, and age.

HPV and Cytology Co-Testing Lowers Risk of Cervical Cancer

HPV and Cytology Co-Testing Lowers Risk of Cervical Cancer

Successive negative HPV and cytology co-testing is linked decrease risks of cervical cancer.

Efficacy of 9-Valent HPV Vaccine in Young Women

Efficacy of 9-Valent HPV Vaccine in Young Women

By

Findings inform further refinement of cervical cancer screening algorithms for vaccinated populations.

HPV Vaccine Linked to Lower Respiratory Papillomatosis Rates

HPV Vaccine Linked to Lower Respiratory Papillomatosis Rates

Incidence of juvenile-onset respiratory papillomatosis declined with the introduction of a HPV vaccination program.

Sign Up for Free e-newsletters